eg017
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 6, 2022 (NCT05674045)
Timeline
Indications
Mechanism of action
- Adrenergic receptorMODULATOR
Adrenergic receptor modulator
- Alpha-1A adrenergic receptor (ADRA1A) ↗
- Alpha-2A adrenergic receptor (ADRA2A) ↗
- Beta-1 adrenergic receptor (ADRB1) ↗
- Beta-2 adrenergic receptor (ADRB2) ↗
- Alpha-2C adrenergic receptor (ADRA2C) ↗
- Alpha-1D adrenergic receptor (ADRA1D) ↗
- Alpha-1B adrenergic receptor (ADRA1B) ↗
- Alpha-2B adrenergic receptor (ADRA2B) ↗
- Beta-3 adrenergic receptor (ADRB3) ↗
- Beta-2 adrenergic receptor
- Beta-1 adrenergic receptor
- Alpha-2a adrenergic receptor
- Alpha-1d adrenergic receptor
- Alpha-1a adrenergic receptor
- Alpha-1b adrenergic receptor
- Alpha-2b adrenergic receptor
- Alpha-2c adrenergic receptor
- Beta-3 adrenergic receptor
- Adrenergic receptor beta
- Adrenergic receptor alpha-1
- Adrenergic receptor alpha-2
- Adrenergic receptor alpha
- Adrenergic receptors; alpha-1 A & B
- Adrenergic receptor beta; ADRB1 & ADRB2
- Adrenergic receptor beta; ADRB1 & ADRB3
- Alpha adrenergic receptor (1a and 1d)
- Beta-2 adrenergic receptor and beta-3 adrenergic receptor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06133166 | Phase 2 | Sep 20, 2023 | GeneScience Pharmaceuticals Co., Ltd. |
| NCT05673694 | Phase 1 | Mar 8, 2023 | GeneScience Pharmaceuticals Co., Ltd. |
| NCT05674045 | Phase 2 | Jan 6, 2022 | GeneScience Pharmaceuticals Co., Ltd., Peking University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GeneScience Pharmaceuticals Co., Ltd. | For profit | 3 | 3 | 2 | 2022 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1